FIELD: medicine.
SUBSTANCE: claimed invention relates to field of biotechnology. Claimed antibodies which bind with fibronectin type-III domain 1 (FND1) of AXL protein and cause AXL deactivation, as well as application of said antibodies for suppression of growth of malignant tumour, mediated by AXL, hybridomas, producing them and composition for suppression of growth of AXL-mediated malignant tumour, which contains antibody in accordance with claimed invention as active ingredient.
EFFECT: obtaining antibodies for suppression of malignant tumour growth.
12 cl, 7 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-AXL ANTIBODIES | 2008 |
|
RU2506276C2 |
| MONOCLONAL ANTIBODY AND HYBRIDOMA PRODUCING ITS | 2004 |
|
RU2312109C2 |
| HUMANISED ANTI-AXL ANTIBODIES | 2010 |
|
RU2571224C2 |
| TUMOUR-TARGETED MONOCLONAL ANTIBODIES AGAINST FZD10 AND THEIR APPLICATION | 2006 |
|
RU2412203C2 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER | 2011 |
|
RU2567657C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2603742C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2598258C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER | 2011 |
|
RU2597971C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT GROWTH | 2012 |
|
RU2610428C2 |
